# IGC Pharma, Inc.: Form 10-Q for the period ended Sep 30, 2015

- Company: [IGC Pharma, Inc.](/companies/igc.md) (CIK 1326205)
- Form: 10-Q
- Filed: 2015-11-13
- Accepted by EDGAR: Nov 13, 2015, 16:04 ET
- Period: 2015-09-30
- Accession: 0001185185-15-002954
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1326205/000118518515002954/indiaglobalization10q093015.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1326205/000118518515002954/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-07-01 to 2015-09-30 | $2.1m | us-gaap:Revenues |
| Revenue | 6 months, 2015-04-01 to 2015-09-30 | $3.9m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2015-07-01 to 2015-09-30 | $1.9m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2015-04-01 to 2015-09-30 | $3.5m | us-gaap:CostOfRevenue |
| Selling, general and administrative | 3 months, 2015-07-01 to 2015-09-30 | $525.4k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2015-04-01 to 2015-09-30 | $830.8k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2015-07-01 to 2015-09-30 | −$508.2k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2015-04-01 to 2015-09-30 | −$765.6k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2015-07-01 to 2015-09-30 | $66.8k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2015-04-01 to 2015-09-30 | $128.7k | us-gaap:InterestExpense |
| Income tax | 3 months, 2015-07-01 to 2015-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2015-04-01 to 2015-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2015-07-01 to 2015-09-30 | −$623.4k | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2015-04-01 to 2015-09-30 | −$1.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2015-07-01 to 2015-09-30 | −$0.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2015-04-01 to 2015-09-30 | −$0.07 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2015-07-01 to 2015-09-30 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2015-04-01 to 2015-09-30 | −$0.07 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2015-07-01 to 2015-09-30 | 14,995,130 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2015-04-01 to 2015-09-30 | 14,995,130 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2015-04-01 to 2015-09-30 | $7.3k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2015-09-30 | $637.9k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-09-30 | $3.5m | us-gaap:AssetsCurrent |
| Total assets | at 2015-09-30 | $18.8m | us-gaap:Assets |
| Current liabilities | at 2015-09-30 | $1.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2015-09-30 | $4.7m | us-gaap:Liabilities |
| Long-term debt | at 2015-09-30 | $294.6k | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | at 2015-09-30 | $510.9k | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2015-09-30 | $13.6m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 16,837 characters.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed financial statements and related notes that appear elsewhere in this Quarterly Report on Form 10-Q, and the Annual Report on Form 10-K filed with the SEC on July 13, 2015. In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed in our Annual Report on Form 10-K filed with the SEC on July 13, 2015, including the risk factors set out in Item 1A therein. Therefore, the financial statements included in this Report should be read in conjunction with the audited Consolidated Financial Statements contained in the Company’s Annual Report on Form 10-K filed with the SEC on July 13, 2015.

### Company Overview

India Globalization Capital, Inc. (“IGC”), a Maryland corporation, was organized on April 29, 2005 as a blank check company formed for the purpose of acquiring one or more businesses with operations primarily in India, and now Hong Kong and China, through a merger, capital stock exchange, asset acquisition or other similar business combination or acquisition. On March 8, 2006, the Company completed an initial public offering. Currently IGC is in the process of positioning itself in two of the world’s fastest growing industries -- phytocannabinoid-based biopharmaceuticals and the Internet of Things (“IoT”). In the United States, we develop phytocannabinoid-based therapies for the treatment of a wide range of conditions that are life altering or life threatening; we also build state-of-the art facilities that can be used to grow and extract pharmaceutical grade phytocannabinoids. In Hong Kong, through a subsidiary, we trade and supply electronics for the Internet of Things and health monitoring devices. As part of our legacy business, in India, we engage in leasing equipment to the construction and other industries.

The Internet of Things is the network of physical objects or "things" embedded with electronics, software, sensors and connectivity to enable objects to exchange data with the manufacturer, operator and/or other connected devices. Phytocannabinoids are chemical compounds that exert a range of effects on the human body including, impacting the immune response, gastrointestinal maintenance and motility, muscle functioning, and nervous system response and functioning.

Our short-term plans are to develop, test and patent phytocannabinoid based pharmaceutical therapies, drive our electronics business through partnerships, and build leading edge facilities that can be used to grow and extract pharmaceutical grade phytocannabinoids. Our medium-term plans are to acquire companies or management that can help us advance our bio-pharmaceutical and our technology businesses. Our long-term plan is to establish IGC as a leading provider of phytocannabinoid based pharmaceutical and nutraceutical products.

### Subsidiaries Overview

HK Ironman is a Hong Kong-based company incorporated on December 20, 2010 to acquire PRC Ironman. PRC Ironman was incorporated as Linxi Hefei Economic & Trade Co., Ltd. in China on January 8, 2008. HK Ironman owns 95% of PRC Ironman. PRC Ironman is engaged in the processing of iron ore from sand and dirt at its beneficiation plants in southwest Linxi in the autonomous region of eastern Inner Mongolia. On February 2, 2015, IGC filed a lawsuit for the cancellation of shares that were issued to the shareholders of HK Ironman. The lawsuit is in the preliminary stages and is expected to settle by fiscal year 2017.

Incorporated on February 19, 2007, India Globalization Capital, Mauritius, Limited (IGC-M) is a Mauritius based company that manages and owns all the subsidiaries based in India: IGC Materials, Private Limited (“IGC-MPL”), IGC Logistics, Private Limited (“IGC-LPL”), IGC India Mining and Trading (“IGC-IMT”) and Techni Bharathi Limited (“TBL”). TBL was incorporated on June 19, 1982, in Cochin, India. TBL is an engineering and construction company currently focused on the heavy equipment leasing business. TBL has a focus in the Indian states of Kerala, Karnataka, and Tamil Nadu. On March 31, 2013, TBL became a fully-owned subsidiary of IGC. The other Indian subsidiaries are focused on the trading of materials such as iron ore to customers in India and China.

On January 21, 2013, we incorporated IGC HK Mining and Trading Limited (“IGC-HK”) in Hong Kong. In September 2014, we changed the subsidiary’s name to IGC Cleantech (“IGC-CT”). IGC-CT is a wholly-owned subsidiary of IGC-Mauritius and is not currently an operational subsidiary.

On May 31, 2014, IGC completed the acquisition of 51% of the issued and outstanding share capital of Golden Gate Electronics Limited, a corporation organized and existing under the laws of Hong Kong (formerly "Golden Gate"). This subsidiary, now known as IGC International Limited (“IGC-INT”), operates an e-commerce platform for trading of commodities and electronic components.

On June 27, 2014, we entered into an agreement with TerraSphere Systems LLC to develop multiple facilities to produce organic leafy green vegetables utilizing TerraSphere’s advanced pesticide-free organic indoor farming technology. Under the agreement, we will own 51% of each venture once production is operational, and will have a right of first refusal to participate in all future build-outs. IGC is in the process of negotiating a return of the $150,000 advance.

On December 18, 2014, IGC entered into a Purchase Agreement with Apogee the previous sole owner of the outstanding membership interests of Midtown Partners & Co., LLC, a Florida limited liability company registered as a broker-dealer under the Securities Exchange Act of 1934 (“Midtown”), and acquired, in an initial closing, 24.9% of the outstanding membership interests in Midtown. In consideration of the initial membership interests, we have to issue to Apogee 1,200,000 shares of our common stock (subject to downward adjustment based on certain Q4 2014 financial statement matters). Following the receipt of all required SEC, FINRA and other regulatory approvals, we have agreed to acquire, in a final closing, the remaining 75.1% of the outstanding membership interests in Midtown in consideration of our issuance to Apogee of an additional 700,000 shares of our common stock (subject to downward adjustment based on certain financial statement matters prior to the final closing). As of June 30, 2015, Apogee and Midtown Partners had not received the requisite approvals from FINRA. As a result, pursuant to the terms of the Agreement, there are several penalties that will apply, including the cancellation of 700,000 shares of IGC stock and a penalty of $125,000 payable by Apogee to IGC. The parties are in the process of negotiating a settlement.

### Results of Operations

### Three Months ended September 30, 2015 Compared to Three Months ended September 30, 2014

*Revenue -* Total revenue was $2,055,585 for the three months ended September 30, 2015 as compared to $2,117,816 for the three months ended September 30, 2014. In the three-month periods ended September 30, 2015 and 2014, the revenue was primarily generated by the trading of electronics and rental of heavy equipment. The revenue for the quarter was slightly down due to a slowing down of global economies and the electronics business in the quarter ended 2015.

*Cost of Revenue (excluding depreciation) –* Cost of revenue for the three months ended September 30, 2015 was $1,889,598 as compared to $1,936,513 for the three months ended September 30, 2014. The margins remained approximately the same.

*Selling, General and Administrative* - Selling, general and administrative expenses were $525,353 for the three months ended September 30, 2015 as compared to $791,428 for the three months ended September 30, 2014. After adjustment for ESOP shares and other non-cash expenses the decrease in SG&A year over year is due to our overall cost management.

*Depreciation –* The depreciation expense was approximately $148,855 in the three months ended September 30, 2015 as compared to $155,154 in the three months ended September 30, 2014.

*Interest and other financial expenses –* The interest expense and other financial expenses for the three months ended September 30, 2015 were approximately $66,768 as compared to approximately $79,749 for the three months ended September 30, 2014.

*Other income/(loss) –* Other income loss of $64,671 for the three-month period ended September 30, 2015 contains certain foreign exchange gain/(loss) arising on account of re-measurement of certain intercompany receivables between the US holding company and the foreign subsidiaries. The total foreign exchange loss for the three-month periods ended September 30, 2015 and 2014 amounted to $69,037 and $74,905, respectively, and for the six-month periods ended September 30, 2015 and 2014 amounted to $116,124 and $78,055, respectively. The loss is attributable largely to the depreciation of the Indian rupee against the USD and is considered foreign exchange loss.

*Consolidated Net Income/(loss) –* In the three months ended September 30, 2015, the Company reported a GAAP net income loss of $623,373 and a GAAP EPS loss of $0.04 compared to a GAAP net income loss of $887,399 and a GAAP EPS loss of $0.07 for the three months ended September 30, 2014. The lower loss in the second quarter of fiscal 2016 is attributable to lower selling, general and administrative expenses.

### Six Months Ended September 30, 2015 Compared to Six Months Ended September 30, 2014

*Revenue -* Total revenue was approximately $3,914,394 for the six months ended September 30, 2015, as compared to about $2,881,680 for the six months ended September 30, 2014.

*Cost of Revenue (excluding depreciation) –* Cost of revenue for the six months ended September 30, 2015 was approximately $3,544,367 as compared to approximately $2,623,801 for the six months ended September 30, 2014.

*Selling, General and Administrative* - Selling, general and administrative expenses were about $830,756 for the six months ended September 30, 2015 as compared to approximately $1,869,114 for the six months ended September 30, 2014. The selling, general and administrative expenses for the three months ended September 30, 2014 included an amount of $258,209 towards acquisition costs whereas SG&A for the three months ended September 30, 2015 has none.

*Depreciation –* The depreciation expense was approximately $304,829 in the six months ended September 30, 2015 as compared to about $304,043 in the six months ended September 30, 2014.

*Interest and other financial expenses –* The interest expense and other financial expenses for the six months ended September 30, 2015 were about $128,682 as compared to approximately $140,919 for the six months ended September 30, 2014.

*Other income/(loss) –* The total foreign exchange loss for the six-month period ended September 30, 2015 and September 30, 2014 is $116,124 and $78,055, respectively.

*Consolidated Net Income/ (loss) –* Consolidated net loss for the six months ended September 30, 2015 was approximately $1,006,072 compared to a consolidated net loss of about $2,105,406 for the six months ended September 30, 2014.

### Off-Balance Sheet Arrangements

We do not have any undisclosed investments in special purpose entities or undisclosed borrowings or debt.

### Liquidity and Capital Resources

This liquidity and capital resources discussion compares the consolidated company financial position for the six-month periods ended September 30, 2015 and 2014.

During the six months ended September 30, 2015, cash provided in operating activities was $7,336 as compared to $1,952,070 used during the six months ended September 30, 2014.

During the six months ended September 30, 2015, $46,582 cash was provided by investing activities from continuing operations as compared to $704,087 used during the same period in 2014.

During the six months ended September 30, 2015, net cash used in financing activities was $249,109 as compared to $2,860,535 provided during the same period in 2014.

For the quarter ended September 30, 2015, our non-GAAP cash burn was approximately $101,810 after adjusting for $148,855 of depreciation, $69,037 of non-cash foreign exchange loss, $20,671 of non-cash interest and $283,000 stock issuance related expenses.

At the end of September 30, 2015, our cash and cash equivalents along with restricted cash was $637,923 and working capital of $2,262,179. We currently have sufficient cash to continue business operations with limited expansion.

### Critical Accounting Policies

See Note 2 - Significant Accounting Policies of the Notes to Consolidated Financial Statements in Part I, Item 1 of this report for a discussion of our critical accounting policies.

### Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. This report and the documents incorporated in this report by reference contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Additionally, we or our representatives may, from time to time, make other written or verbal forward-looking statements. In this report and the documents incorporated by reference, we discuss plans, expectations and objectives regarding our business, financial condition and results of operations. Without limiting the foregoing, statements that are in the future tense, and all statements accompanied by terms such as “believe,” “project,” “expect,” “trend,” “estimate,” “forecast,” “assume,” “intend,” “plan,” “target,” “anticipate,” “outlook,” “preliminary,” “will likely result,” “will continue” and variations of them and similar terms are intended to be “forward-looking statements” as defined by federal securities laws. We caution you not to place undue reliance on forward-looking statements, which are based upon assumptions, expectations, plans and projections. Forward-looking statements are subject to risks and uncertainties, including those identified in the “Risk Factors” included in the Company’s Annual report on Form 10-K and in the documents incorporated by reference that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements speak only as of the date when they are made. Except as required by federal securities law, we do not undertake any obligation to update forward-looking statements to reflect events, circumstances, changes in expectations or the occurrence of unanticipated events after the date of those statements. We intend that all forward-looking statements made will be subject to safe harbor protection of the federal securities laws pursuant to Section 27A of the Securities Act and Section 21E of the Exchange Act.

Forward-looking statements are based upon, among other things, our assumptions with respect to:

- competition in exploiting phytocannabinoids for pharmaceutical and nutraceutical applications;
- federal and state legislation for regulating phytocannabinoids;
- public and regulatory reaction to the use of phytocannabinoids;
- growth rate and competition in the electronic components sector;
- our ability to obtain and protect patents for the use of phytocannabinoids;
- our ability to win licenses, contracts and execute on them;
- current and future economic and political conditions;
- overall industry and market performance;
- the impact of accounting pronouncements;
- management’s goals and plans for future operations; and
- other assumptions described in this prospectus supplement underlying or relating to any forward-looking statements.

You should consider the limitations on, and risks associated with, forward-looking statements and not unduly rely on the accuracy of predictions contained in such forward-looking statements. As noted above, these forward-looking statements speak only as of the date when they are made. Moreover, in the future, we may make forward-looking statements through our senior management that involve the risk factors and other matters described in the Company’s Annual report on Form 10-K, as well as other risk factors subsequently identified, including, among others, those identified in our filings with the SEC in our quarterly reports on Form 10-Q and our current reports on Form 8-K.

## Market risk

As filed, 159 characters.

Pursuant to Item 305(e) of Regulation S-K, the Company is not required to provide the information required by this Item as it is a “smaller reporting company.”

## Controls and procedures

As filed, 1,775 characters.

### Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, management conducted an evaluation, under the supervision and with the participation of its Chief Executive Officer (CEO) and its principal financial and accounting officer (PFAO), of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15 and 15d-15 of the Securities Exchange Act of 1934. Based upon that evaluation, our CEO and PFAO concluded that our disclosure controls and procedures are effective.

Disclosure controls and procedures are defined by Rules 13a-15(e) and 15d-15(e) of the Exchange Act as controls and other procedures that are designed to ensure that information required to be disclosed by us in reports filed with the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed under the Exchange Act is accumulated and communicated to our management, including our CEO and PFAO, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal controls over financial reporting during our fiscal quarter ended September 30, 2015 which were identified in conjunction with Management’s evaluation required by paragraph (d) of Rule 13a-15 and 15d-15 under the Exchange Act that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

## Risk factors

As filed, 179 characters.

There have not been any material changes with regard to the risk factors previously disclosed in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2015.

Filed Nov 13, 2015.
Source: SEC EDGAR, the filing index for accession 0001185185-15-002954. Last ingested by Listed: Nov 6, 2026, 16:27 ET. No prices; not investment advice.
